tbuckley/cabot-search huggingface dataset:
Rapid inference of personalised left-ventricular meshes by deformation-based differentiable mesh voxelization
Authors: Thomas Joyce, Stefano Buoso, Christian T. Stoeck, Sebastian Kozerke
Journal: Medical Image Analysis (2022)

We propose a differentiable volumetric mesh voxelization technique based on deformation of a shape-model, and demonstrate that it can be used to predict left-ventricular anatomies directly from magnetic resonance image slice data. The predicted anatomies are volumetric meshes suitable for direct inclusion in biophysical simulations. The proposed method can leverage existing (pixel-based) segmentation networks, and does not require any ground truth paired image and mesh training data. We demonstrate that this approach produces accurate predictions from few slices, and can combine information from images acquired in different views (e.g. fusing shape information from short axis and long axis slices). We demonstrate that the proposed method is several times faster than a state-of-the-art registration based method. Additionally, we show that our method can correct for slice misalignment, and is robust to incomplete and inaccurate input data. We further demonstrate that by fitting a mesh to every frame of 4D data we can determine ejection fraction, stroke volume and strain.
Practical outpatient management of worsening chronic heart failure
Authors: Nicolas Girerd, Nathan Mewton, Jean‐Michel Tartière, Damien Guijarro, Patrick Jourdain, Thibaud Damy, Nicolas Lamblin, Antoni Bayes‐Génis, Pierpaolo Pellicori, James L. Januzzi, Patrick Rossignol, François Roubille
Journal: European Journal of Heart Failure (2022)

Management of worsening heart failure (WHF) has traditionally been hospital-based, but with the rising burden of heart failure (HF), the pressure on healthcare systems exerted by this disease necessitates a different strategy than long (and costly) hospital stays. A strategy for outpatient intravenous (IV) diuretic treatment of WHF has been developed in certain American centres in the past 10 years, whereas European centres have been mostly favouring 'classic' in-hospital management of WHF. Embracing novel, outpatient approaches for treating WHF could substantially reduce the burden on healthcare systems while improving patient's satisfaction and quality of life. The present article is intended to provide essential knowledge and practical guidelines aimed at helping clinicians implement these new ambulatory approaches using day hospital and/or at-home hospitalization. The topics addressed by our group of HF experts include the pathophysiological background of diuretic therapy, the most suitable profile of WHF that may be managed in an ambulatory setting, the pharmacological protocols that can be used, as well as a detailed description of healthcare structures that can be proposed to deliver these ambulatory care interventions. The practical aspects of day hospital and hospital-at-home IV diuretic administration are specifically emphasized. The algorithm provided along with the practical IV diuretic protocols should assist HF clinicians in implementing this new approach in their local clinical setting.
Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization
Authors: Todd C. Lee, Simone Vigod, Émilie Bortolussi-Courval, Ryan Hanula, David R. Boulware, Eric J. Lenze, Angela M. Reiersen, Emily G. McDonald
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Widely available and affordable options for the outpatient management of COVID-19 are needed, particularly for therapies that prevent hospitalization. <h3>Objective</h3> To perform a meta-analysis of the available randomized clinical trial evidence for fluvoxamine in the outpatient management of COVID-19. <h3>Data Sources</h3> World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov. <h3>Study Selection</h3> Studies with completed outpatient trials with available results that compared fluvoxamine with placebo were included. <h3>Data Extraction and Synthesis</h3> The PRISMA 2020 guidelines were followed and study details in terms of inclusion criteria, trial demographics, and the prespecified outcome of all-cause hospitalization were extracted. Risk of bias was assessed by the Cochrane Risk of Bias 2 tool and a bayesian random effects meta-analysis with different estimates of prior probability was conducted: a weakly neutral prior (50% chance of efficacy with 95% CI for risk ratio [RR] between 0.5 and 2.0) and a moderately optimistic prior (85% chance of efficacy). A frequentist random-effects meta-analysis was conducted as a senstivity analysis, and the results were contextualized by estimating the probability of any association (RR ≤ 1) and moderate association (RR ≤ 0.9) with reduced hospitalization. <h3>Main Outcomes and Measures</h3> All-cause hospitalization. <h3>Results</h3> This systematic review and meta-analysis of 3 randomized clinical trials and included 2196 participants. The RRs for hospitalization were 0.78 (95% CI, 0.58-1.08) for the bayesian weakly neutral prior, 0.73 (95% CI, 0.53-1.01) for the bayesian moderately optimistic prior, and 0.75 (95% CI, 0.58-0.97) for the frequentist analysis. Depending on the scenario, the probability of any association with reduced hospitalization ranged from 94.1% to 98.6%, and the probability of moderate association ranged from 81.6% to 91.8%. <h3>Conclusions and Relevance</h3> In this systematic review and meta-analysis of data from 3 trials, under a variety of assumptions, fluvoxamine showed a high probability of being associated with reduced hospitalization in outpatients with COVID-19. Ongoing randomized trials are important to evaluate alternative doses, explore the effectiveness in vaccinated patients, and provide further refinement to these estimates. Meanwhile, fluvoxamine could be recommended as a management option, particularly in resource-limited settings or for individuals without access to SARS-CoV-2 monoclonal antibody therapy or direct antivirals.
Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6
Authors: Alyssa Clay-Gilmour, Subhayan Chattopadhyay, Michelle A. T. Hildebrandt, Hauke Thomsen, Niels Weinhold, Pavel Vodicka, Ludmila Vodickova, Per Hoffmann, Markus M. Nöthen, Karl-Heinz Jöckel, Börge Schmidt, Christian Langer, Roman Hajek, Göran Hallmans, Ulrika Pettersson-Kymmer, Claes Ohlsson, Florentin Späth, Richard Houlston, Hartmut Goldschmidt, Elisabet E. Manasanch, Aaron Norman, Shaji Kumar, S. Vincent Rajkumar, Susan Slager, Asta Försti, Celine M. Vachon, Kari Hemminki
Journal: Blood Cancer Journal (2022)
Emerging nanotherapeutics alleviating rheumatoid arthritis by readjusting the seeds and soils
Authors: Wenjing Zhang, Yang Chen, Qin Liu, Mei Zhou, Kang Wang, Yongzhong Wang, Jiusheng Nie, Shuangying Gui, Daiyin Peng, Zhonggui He, Zhenbao Li
Journal: Journal of Controlled Release (2022)
The age-dependent association of risk factors with pancreatic cancer
Authors: C. Yuan, J. Kim, Q.L. Wang, A.A. Lee, A. Babic, L.T. Amundadottir, A.P. Klein, D. Li, M.L. McCullough, G.M. Petersen, H.A. Risch, R.Z. Stolzenberg-Solomon, K. Perez, K. Ng, E.L. Giovannucci, M.J. Stampfer, P. Kraft, B.M. Wolpin, L.T. Amundadottir, E. Ardanaz, A.A. Arslan, L.E. Beane-Freeman, P.M. Bracci, B. Bueno-de-Mesquita, M. Du, S. Gallinger, G.G. Giles, P.J. Goodman, V.A. Katzke, A.P. Klein, C. Kooperberg, P. Kraft, D. Li, N. Malats, L.L. Marchand, M.L. McCullough, R.L. Milne, J.P. Neoptolemos, S. Perdomo, G.M. Petersen, H.A. Risch, X.O. Shu, R.Z. Stolzenberg-Solomon, S.K. Van Den Eeden, K. Visvanathan, E. White, B.M. Wolpin, W. Zheng
Journal: Annals of Oncology (2022)
IFNα Potentiates Anti–PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment
Authors: Bo Hu, Mincheng Yu, Xiaolu Ma, Jialei Sun, Chenglong Liu, Chunyan Wang, Suiyi Wu, Peiyao Fu, Zhen Yang, Yungang He, Yuanyuan Zhu, Cheng Huang, Xinrong Yang, Yinghong Shi, Shuangjian Qiu, Huichuan Sun, Andrew X. Zhu, Jian Zhou, Yang Xu, Di Zhu, Jia Fan
Journal: Cancer Discovery (2022)

The overall response rate for anti-PD-1 therapy remains modest in hepatocellular carcinoma (HCC). We found that a combination of IFNα and anti-PD-1-based immunotherapy resulted in enhanced antitumor activity in patients with unresectable HCC. In both immunocompetent orthotopic and spontaneous HCC models, IFNα therapy synergized with anti-PD-1 and the combination treatment led to significant enrichment of cytotoxic CD27+CD8+ T cells. Mechanistically, IFNα suppressed HIF1α signaling by inhibiting FosB transcription in HCC cells, resulting in reduced glucose consumption capacity and consequentially establishing a high-glucose microenvironment that fostered transcription of the T-cell costimulatory molecule Cd27 via mTOR-FOXM1 signaling in infiltrating CD8+ T cells. Together, these data reveal that IFNα reprograms glucose metabolism within the HCC tumor microenvironment, thereby liberating T-cell cytotoxic capacities and potentiating the PD-1 blockade-induced immune response. Our findings suggest that IFNα and anti-PD-1 cotreatment is an effective novel combination strategy for patients with HCC.Our study supports a role of tumor glucose metabolism in IFNα-mediated antitumor immunity in HCC, and tumor-infiltrating CD27+CD8+ T cells may be a promising biomarker for stratifying patients for anti-PD-1 therapy. See related commentary by Kao et al., p. 1615. This article is highlighted in the In This Issue feature, p. 1599.
Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma
Authors: Lakshmi Nayak, Nathan Standifer, Jorg Dietrich, Jennifer L. Clarke, Gavin P. Dunn, Michael Lim, Timothy Cloughesy, Hui K. Gan, Elizabeth Flagg, Elizabeth George, Sarah Gaffey, Julia Hayden, Christina Holcroft, Patrick Y. Wen, Mary Macri, Andrew J. Park, Toni Ricciardi, Aileen Ryan, Paul Schwarzenberger, Ralph Venhaus, Melissa de los Reyes, Nicholas M. Durham, Todd Creasy, Raymond Y. Huang, Thomas Kaley, David A. Reardon
Journal: Clinical Cancer Research (2022)

PD-L1 is upregulated in glioblastoma and supports immunosuppression. We evaluated PD-L1 blockade with durvalumab among glioblastoma cohorts and investigated potential biomarkers.MGMT unmethylated newly diagnosed patients received radiotherapy plus durvalumab (cohort A; n = 40). Bevacizumab-naïve, recurrent patients received durvalumab alone (cohort B; n = 31) or in combination with standard bevacizumab (cohort B2; n = 33) or low-dose bevacizumab (cohort B3; n = 33). Bevacizumab-refractory patients received durvalumab plus bevacizumab (cohort C; n = 22). Primary endpoints were: OS-12 (A), PFS-6 (B, B2, B3), and OS-6 (C). Exploratory biomarkers included: a systematic, quantitative, and phenotypic evaluation of circulating immune cells; tumor mutational burden (TMB); and tumor immune activation signature (IAS).No cohort achieved the primary efficacy endpoint. Outcome was comparable among recurrent, bevacizumab-naïve cohorts. No unexpected toxicities were observed. A widespread reduction of effector immune cell subsets was noted among recurrent patients compared with newly diagnosed patients that was partially due to dexamethasone use. A trend of increased CD8+Ki67+ T cells at day 15 was noted among patients who achieved the primary endpoint and were not on dexamethasone. Neither TMB nor IAS predicted outcome.Patients with recurrent glioblastoma have markedly lower baseline levels of multiple circulating immune cell subsets compared with newly diagnosed patients. An early increase in systemic Ki67+CD8+ cells may warrant further evaluation as a potential biomarker of therapeutic benefit among patients with glioblastoma undergoing checkpoint therapy. Dexamethasone decreased immune cell subsets. PD-L1 blockade and combination with standard or reduced dose bevacizumab was ineffective.
Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100
Authors: Alissa Visram, S. Vincent Rajkumar, Prashant Kapoor, Angela Dispenzieri, Martha Q. Lacy, Morie A. Gertz, Francis K. Buadi, Suzanne R. Hayman, David Dingli, Taxiarchis Kourelis, Wilson Gonsalves, Rahma Warsame, Eli Muchtar, Nelson Leung, Robert A. Kyle, Shaji K. Kumar
Journal: Leukemia (2022)
Trends in Clinical Presentation, Management, and Outcomes of STEMI in Patients With COVID-19
Authors: Santiago Garcia, Payam Dehghani, Larissa Stanberry, Cindy Grines, Rajan A.G. Patel, Keshav R. Nayak, Avneet Singh, Wah Wah Htun, Ameer Kabour, Nima Ghasemzadeh, Cristina Sanina, Joseph Aragon, M. Chadi Alraies, Catherine Benziger, Brynn Okeson, Ross Garberich, Frederick G. Welt, Laura Davidson, Abdul Moiz Hafiz, Deepak Acharya, Jay Stone, Aditya Mehra, Shy Amlani, Ehtisham Mahmud, Jay Giri, Mehmet Yildiz, Timothy D. Henry
Journal: Journal of the American College of Cardiology (2022)
Greater proportion of patients report an acceptable symptom state after ACL reconstruction compared with non-surgical treatment: a 10-year follow-up from the Swedish National Knee Ligament Registry
Authors: Kajsa Persson, Emma Bergerson, Eleonor Svantesson, Alexandra Horvath, Jon Karlsson, Volker Musahl, Kristian Samuelsson, Eric Hamrin Senorski
Journal: British Journal of Sports Medicine (2022)

To compare the proportion of patients with anterior cruciate ligament (ACL) injury reporting an acceptable symptom state, between non-surgical and surgical treatment during a 10-year follow-up.Data were extracted from the Swedish National Knee Ligament Registry. Exceeding the Patient Acceptable Symptom State (PASS) for the Knee injury and Osteoarthritis Outcome Score (KOOS) was the primary outcome. The PASS and KOOS4 (aggregated KOOS without the activities of daily living (ADL) subscale) were compared cross-sectionally at baseline and 1, 2, 5 and 10 years after ACL injury, where patients treated non-surgically were matched with the maximum number of patients with ACL reconstruction for age, sex and activity at injury.The non-surgical group consisted of 982 patients, who were each matched against 9 patients treated with ACL reconstruction (n=8,838). A greater proportion of patients treated with ACL reconstruction exceeded the PASS in KOOS pain, ADL, sports and recreation, and quality of life compared with patients treated non-surgically at all follow-ups. With respect to quality of life, significantly more patients undergoing ACL reconstruction achieved a PASS compared with patients receiving non-surgical treatment at all follow-ups except at baseline, with differences ranging between 11% and 25%; 1 year -25.4 (-29.1; -21.7), 2 years -16.9 (-21.2; -12.5), 5 years -11.0 (-16.9; -5.1) and 10 years -24.8 (-36.0; -13.6). The ACL-reconstructed group also reported statistically greater KOOS4 at all follow-ups.A greater proportion of patients treated with ACL reconstruction report acceptable knee function, including higher quality of life than patients treated non-surgically at cross-sectional follow-ups up to 10 years after the treatment of an ACL injury.
TCTAP C-006 Emergency Complex Left Main Bifurcation PCI in a Case of NSTEMI With Pulmonary Edema and Cardiogenic Shock: Should We Strive for Angiographic Perfection in Unfavorable Anatomy?
Authors: Vipin Thomachan, Ali Shamsi, Ahmed Siddiqui, Gohar Jamil
Journal: Journal of the American College of Cardiology (2022)
<i>Enterobacteriaceae</i> and <i>Bacteroidaceae</i> provide resistance to travel-associated intestinal colonization by multi-drug resistant <i>Escherichia coli</i>
Authors: Matthew Davies, Gianluca Galazzo, Jarne M. van Hattem, Maris S. Arcilla, Damian C. Melles, Menno D. de Jong, Constance Schultsz, Petra Wolffs, Alan McNally, Willem van Schaik, John Penders
Journal: Gut Microbes (2022)

Previous studies have shown high acquisition risks of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) among international travelers visiting antimicrobial resistance (AMR) hotspots. Although antibiotic use and travelers' diarrhea have shown to influence the ESBL-E acquisition risk, it remains largely unknown whether successful colonization of ESBL-E during travel is associated with the composition, functional capacity and resilience of the traveler's microbiome. The microbiome of pre- and post-travel fecal samples from 190 international travelers visiting Africa or Asia was profiled using whole metagenome shotgun sequencing. A metagenomics species concept approach was used to determine the microbial composition, population diversity and functional capacity before travel and how it is altered longitudinally. Eleven travelers were positive for ESBL-E before travel and removed from the analysis. Neither the microbial richness (Chao1), diversity (effective Shannon) and community structure (Bray–Curtis dissimilarity) in pretravel samples nor the longitudinal change of these metrics during travel were predictive for ESBL-E acquisition. A zero-inflated two-step beta-regression model was used to determine how the longitudinal change in both prevalence and abundance of each taxon was related to ESBL acquisition. There were detected increases in both the prevalence and abundance of Citrobacter freundii and two members of the genus Bacteroides, in association with remaining uncolonized by ESBL-E. These results highlight the potential of these individual microbes as a microbial consortium to prevent the acquisition of ESBL-E. The ability to alter a person's colonization resistance to a bacterium could be key to intervention strategies that aim to minimize the spread of MDR bacteria.
Potential Bias About the Association Between Weight Loss Surgery and COVID-19 Infection
Authors: Pei-En Kao, Amy Ker, James Cheng-Chung Wei
Journal: JAMA Surgery (2022)

Ali Aminian, MD; Chao Tu, MS; Alex Milinovich, BA; Kathy E. Wolski, MPH; Michael W. Kattan, PhD; Steven E. Nissen, MD
TCTAP C-162 Severe Hand Hematoma Sparing the Forearm Post Percutaneous Coronary Intervention via Distal Radial Artery
Authors: Mohd Asyiq Al-Fard Bin Mohd Raffali, Shawal Faizal Mohamad, Diyana Farouk, Hamat Hamdi Che Hassan
Journal: Journal of the American College of Cardiology (2022)
Monocytes transition to macrophages within the inflamed vasculature via monocyte CCR2 and endothelial TNFR2
Authors: Vijayashree Mysore, Suhail Tahir, Kazuhiro Furuhashi, Jatin Arora, Florencia Rosetti, Xavier Cullere, Pascal Yazbeck, Miroslav Sekulic, Madeleine E. Lemieux, Soumya Raychaudhuri, Bruce H. Horwitz, Tanya N. Mayadas
Journal: The Journal of Experimental Medicine (2022)

Monocytes undergo phenotypic and functional changes in response to inflammatory cues, but the molecular signals that drive different monocyte states remain largely undefined. We show that monocytes acquire macrophage markers upon glomerulonephritis and may be derived from CCR2+CX3CR1+ double-positive monocytes, which are preferentially recruited, dwell within glomerular capillaries, and acquire proinflammatory characteristics in the nephritic kidney. Mechanistically, the transition to immature macrophages begins within the vasculature and relies on CCR2 in circulating cells and TNFR2 in parenchymal cells, findings that are recapitulated in vitro with monocytes cocultured with TNF-TNFR2-activated endothelial cells generating CCR2 ligands. Single-cell RNA sequencing of cocultures defines a CCR2-dependent monocyte differentiation path associated with the acquisition of immune effector functions and generation of CCR2 ligands. Immature macrophages are detected in the urine of lupus nephritis patients, and their frequency correlates with clinical disease. In conclusion, CCR2-dependent functional specialization of monocytes into macrophages begins within the TNF-TNFR2-activated vasculature and may establish a CCR2-based autocrine, feed-forward loop that amplifies renal inflammation.
Hyperhidrosis is associated with sleep disturbances, daytime tiredness, stress, and depression: A retrospective cohort study from the Danish Blood Donor Study
Authors: Mattias Henning, Kristina Ibler, Isabella Loft, Poul Jennum, Maria Didriksen, Henrik Ullum, Christian Erikstrup, Kaspar Nielsen, Mie Topholm Bruun, Henrik Hjalgrim, Erik Sørensen, Khoa Dinh, Lise Wegner Thørner, Gregor B. Jemec, Ole Pedersen
Journal: Journal of the American Academy of Dermatology (2022)
Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2
Authors: Olha Puhach, Kenneth Adea, Nicolas Hulo, Pascale Sattonnet, Camille Genecand, Anne Iten, Frédérique Jacquérioz, Laurent Kaiser, Pauline Vetter, Isabella Eckerle, Benjamin Meyer
Journal: Nature Medicine (2022)
Association of Breast-Conserving Therapy With Measures of Long-term Quality of Life Compared With Mastectomy and Reconstruction
Authors: Sudheer Vemuru, Clara N. Lee, Sarah E. Tevis
Journal: JAMA Surgery (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal